Mizuho Securities Reiterates Buy Rating, $12 PT on IN8bio (INAB), Sees Latest Presentations as "Supportive of INAB's Drug-resistant Immunotherapy Platform"

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. NAVN
4. CHWY
5. HUMA
6. USO
7. SPCX
8. CME
9. cASY
10. TSLA

Go back to Mizuho Securities Reiterates Buy Rating, $12 PT on IN8bio (INAB), Sees Latest Presentations as "Supportive of INAB's Drug-resistant Immunotherapy Platform"
(NASDAQ: INAB) Delayed: 1.40 --0 (-0%)
Previous Close $1.40    52 Week High $ 
Open $1.40    52 Week Low $ 
Day High $1.40    P/E N/A 
Day Low $1.40    EPS $ 
Volume 743